SML0422
伊司茶碱
≥98% (HPLC)
别名:
(E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine, 8-[(1E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, KW-6002
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H24N4O4
化学文摘社编号:
分子量:
384.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
SMILES string
CCN1C(=O)N(CC)c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2C1=O
InChI key
IQVRBWUUXZMOPW-PKNBQFBNSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL (clear solution)
storage temp.
2-8°C
Quality Level
Gene Information
human ... ADORA2A(135)
Biochem/physiol Actions
Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist which has been investigated for use in Parkinson′s Disease.
Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist.
Features and Benefits
This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Giana P Cognato et al.
Journal of neurochemistry, 112(2), 453-462 (2009-11-03)
Seizures early in life cause long-term behavioral modifications, namely long-term memory deficits in experimental animals. Since caffeine and adenosine A(2A) receptor (A(2A)R) antagonists prevent memory deficits in adult animals, we now investigated if they also prevented the long-term memory deficits
William Knebel et al.
Journal of clinical pharmacology, 51(1), 40-52 (2010-03-05)
This model-based analysis quantifies the population pharmacokinetics (PK) of orally administered istradefylline, a selective adenosine A(2A) receptor antagonist, in healthy subjects and patients with Parkinson's disease, including the estimation of covariate effects on istradefylline PK parameters. Istradefylline plasma concentration data
Geoffrey B Varty et al.
Psychopharmacology, 200(3), 393-401 (2008-07-03)
Adenosine and dopamine interact within the striatum to control striatopallidal output and globus pallidus GABA release. Manipulating striatal adenosine transmission via blockade of the A2A receptor subtype can compensate for the reduced dopamine activity within the striatum that underlies movement
Yoshikuni Mizuno et al.
Movement disorders : official journal of the Movement Disorder Society, 25(10), 1437-1443 (2010-07-16)
The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on
Robert A Hauser et al.
Movement disorders : official journal of the Movement Disorder Society, 23(15), 2177-2185 (2008-10-04)
The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW-6002) is an
商品
We offers many products related to adenosine receptors for your research needs.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持